MX2014007042A - Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu. - Google Patents

Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.

Info

Publication number
MX2014007042A
MX2014007042A MX2014007042A MX2014007042A MX2014007042A MX 2014007042 A MX2014007042 A MX 2014007042A MX 2014007042 A MX2014007042 A MX 2014007042A MX 2014007042 A MX2014007042 A MX 2014007042A MX 2014007042 A MX2014007042 A MX 2014007042A
Authority
MX
Mexico
Prior art keywords
buprenorphine
opioid receptor
compositions
receptor antagonists
composition
Prior art date
Application number
MX2014007042A
Other languages
English (en)
Inventor
Daniel Deaver
Elliot Ehrich
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MX2014007042A publication Critical patent/MX2014007042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona a una composición que comprende buprenorfina y un antagonista del receptor opioide mu, en donde la composición se caracteriza por un índice de actividad de Antagonista-Agonista (AAnAI) de entre aproximadamente 0.7 y aproximadamente 2.2; en donde (ver Fórmula).
MX2014007042A 2011-12-15 2012-12-14 Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu. MX2014007042A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (1)

Publication Number Publication Date
MX2014007042A true MX2014007042A (es) 2015-01-22

Family

ID=47757653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007042A MX2014007042A (es) 2011-12-15 2012-12-14 Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.

Country Status (24)

Country Link
US (8) US8822488B2 (es)
EP (3) EP2790702B1 (es)
JP (2) JP6038170B2 (es)
KR (1) KR101996108B1 (es)
CN (2) CN106727562B (es)
AU (1) AU2012351806C1 (es)
BR (1) BR112014012409B8 (es)
CA (1) CA2858812C (es)
CY (1) CY1121081T1 (es)
DK (1) DK3153171T3 (es)
EA (1) EA030609B8 (es)
ES (2) ES2692771T3 (es)
HR (1) HRP20181950T1 (es)
HU (1) HUE041883T2 (es)
IL (1) IL232785B (es)
LT (1) LT3153171T (es)
MX (1) MX2014007042A (es)
PL (1) PL3153171T3 (es)
PT (1) PT3153171T (es)
RS (1) RS58322B1 (es)
SI (1) SI3153171T1 (es)
TR (1) TR201815154T4 (es)
WO (1) WO2013088243A1 (es)
ZA (1) ZA201405029B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600379A (en) 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US8822488B2 (en) * 2011-12-15 2014-09-02 Alkermes Pharma Ireland Limited Compositions of buprenorphine and μ antagonists
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9133125B2 (en) 2013-05-24 2015-09-15 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
EP3292116B8 (en) 2015-02-02 2021-11-24 Valo Health, Inc. 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (es) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
AR005423A1 (es) 1996-01-10 1999-06-23 Smithkline Beecham Spa Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados.
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
AU2713502A (en) 2000-10-31 2002-05-15 Rensselaer Polytech Inst 8-carboxamido-2,6-methano-3-benzazocines
PT1485051E (pt) 2002-03-20 2008-07-09 Euro Celtique Sa Processo de administração da buprenorfina para o tratamento da depressão
US20050222204A1 (en) 2002-05-30 2005-10-06 Mitch Charles H Opioid receptor antagonists
EP1748978B1 (en) 2004-05-14 2014-06-04 Janssen Pharmaceutica NV Carboxamido opioid compounds
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
EP1817291A1 (en) 2004-11-05 2007-08-15 Rensselaer Polytechnic Institute 4-hydroxybenzomorphans
EA015376B1 (ru) 2005-03-02 2011-08-30 Никомед Гмбх СОЛИ ПРОИЗВОДНЫХ 6-ГЕТЕРОАРИЛ-(1,2,3,4,4a,10b)-ГЕКСАГИДРОФЕНАНТРИДИНА И ИХ ПРИМЕНЕНИЕ
EP2134330B1 (en) 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
KR101519682B1 (ko) 2007-08-09 2015-05-19 렌슬러 폴리테크닉 인스티튜트 4급 오피오이드 카르복스아미드
TR201809734T4 (tr) * 2008-02-14 2018-07-23 Alkermes Inc Seçici opioid bileşikler.
US8138169B2 (en) * 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20120149724A1 (en) 2009-06-04 2012-06-14 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
NZ600379A (en) * 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
US8822488B2 (en) * 2011-12-15 2014-09-02 Alkermes Pharma Ireland Limited Compositions of buprenorphine and μ antagonists
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9656961B2 (en) * 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms

Also Published As

Publication number Publication date
US20160256450A1 (en) 2016-09-08
CN104159586A (zh) 2014-11-19
EA030609B1 (ru) 2018-08-31
ES2791764T3 (es) 2020-11-05
PT3153171T (pt) 2018-11-16
ZA201405029B (en) 2015-10-28
US20190247387A1 (en) 2019-08-15
BR112014012409B8 (pt) 2022-09-13
RS58322B1 (sr) 2019-03-29
JP2016222706A (ja) 2016-12-28
US10314838B2 (en) 2019-06-11
EP2790702B1 (en) 2020-04-01
WO2013088243A1 (en) 2013-06-20
ES2692771T3 (es) 2018-12-05
US10188643B2 (en) 2019-01-29
CA2858812C (en) 2019-02-26
JP6038170B2 (ja) 2016-12-07
US9918978B2 (en) 2018-03-20
US20170056392A1 (en) 2017-03-02
JP6403726B2 (ja) 2018-10-10
TR201815154T4 (tr) 2018-11-21
EA201491153A1 (ru) 2015-04-30
HRP20181950T1 (hr) 2019-03-22
EP3415148A1 (en) 2018-12-19
EP3153171A1 (en) 2017-04-12
JP2015505853A (ja) 2015-02-26
US8822488B2 (en) 2014-09-02
BR112014012409B1 (pt) 2022-08-23
CN106727562B (zh) 2019-07-05
IL232785B (en) 2021-04-29
US10806731B2 (en) 2020-10-20
AU2012351806A1 (en) 2014-05-15
EP2790702A1 (en) 2014-10-22
BR112014012409A2 (pt) 2017-06-13
KR20140107258A (ko) 2014-09-04
EP3153171B1 (en) 2018-09-19
US20180078543A1 (en) 2018-03-22
US20210196703A1 (en) 2021-07-01
DK3153171T3 (en) 2018-11-19
HUE041883T2 (hu) 2019-06-28
SI3153171T1 (sl) 2019-01-31
CY1121081T1 (el) 2019-12-11
US9498474B2 (en) 2016-11-22
LT3153171T (lt) 2018-12-10
US9913837B2 (en) 2018-03-13
CN106727562A (zh) 2017-05-31
KR101996108B1 (ko) 2019-10-01
US20130190342A1 (en) 2013-07-25
US20180078542A1 (en) 2018-03-22
IL232785A0 (en) 2014-07-31
NZ624056A (en) 2016-07-29
CA2858812A1 (en) 2013-06-20
US20150051240A1 (en) 2015-02-19
PL3153171T3 (pl) 2019-02-28
AU2012351806C1 (en) 2016-06-16
EA030609B8 (ru) 2018-10-31
AU2012351806B2 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
MX2014007042A (es) Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
MY172806A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
HK1187045A1 (en) Buprenorphine analogs as opioid receptor agonists and or antagonists
MX2012012897A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta-2 y como antagonistas muscarinicos m3.
HK1246811A1 (zh) Mu阿片受體激動劑類似物的內嗎啡肽
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MX2011011156A (es) COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
ATE502939T1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
MX2014004433A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agosnitas adrenergicos beta 2 y como antagonistas muscarinicos m3.
MX2018015087A (es) Antagonistas de receptores de opiaceos perifericos y usos de los mismos.
MX336366B (es) Antagonistas del receptor opioide periferico y usos de los mismos.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
JO3154B1 (ar) عوامل مضادة لـ trpv4
MX351611B (es) Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
MX2014002473A (es) Compuestos (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1 / antagonistas 5 -ht2a de actividad doble.
MY150062A (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
MX2013005622A (es) Compuestos 3-fenilsulfanilmetil-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
MX2013005623A (es) Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.
UA108659C2 (xx) Аналоги бупренорфіну
UA108104C2 (uk) ПОХІДНІ ЦИКЛОГЕКСИЛАМІНУ, ЩО МАЮТЬ АГОНІСТИЧНУ АКТИВНІСТЬ ПО ВІДНОШЕННЮ ДО β2 АДРЕНЕРГІЧНОГО РЕЦЕПТОРА І АНТАГОНІСТИЧНОЇ АКТИВНОСТІ ПО ВІДНОШЕННЮ ДО M3 МУСКАРИНОВОГО РЕЦЕПТОРА
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists

Legal Events

Date Code Title Description
FG Grant or registration